Related Experiment Videos
The use of aztreonam in the cystic fibrosis patient
1Department of Pathology, School of Medicine, University of Utah, Salt Lake City 84132.
Abstract:
Eradication of pulmonary infection by Pseudomonas aeruginosa in cystic fibrosis (CF) patients has long presented a significant challenge to the medical community. Many antimicrobial agents have proved incompletely effective against this persistent pathogen, and even the aminoglycosides, which represent the traditional therapy for such infections, have been associated with considerable toxicity and resistance. The monobactam antibacterial agent aztreonam is used both as single-agent therapy and in combination with other drugs. Several controlled, clinical trials have demonstrated the efficacy of aztreonam in the treatment of CF patients with pulmonary exacerbations caused by P. aeruginosa. The only side effect of aztreonam therapy commonly encountered in these studies was elevation of hepatic transaminase concentrations; this effect was of uncertain significance. It was concluded that aztreonam may offer clinical efficacy comparable to that provided by the combination of tobramycin plus azlocillin. Further, there does not seem to be any appreciable difference in the development of resistance to aztreonam compared with traditional therapies.
Insights
Aztreonam effectively treats Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) patients. This antibiotic shows comparable efficacy to traditional therapies with a favorable safety profile, offering a valuable option for CF care.
Area of Science:
- Pulmonary Medicine
- Infectious Diseases
- Pharmacology
Background:
- Pseudomonas aeruginosa lung infections are a major challenge in cystic fibrosis (CF).
- Traditional therapies like aminoglycosides have limitations including toxicity and resistance.
- Aztreonam, a monobactam antibiotic, is an alternative treatment option.
Purpose of the Study:
- To evaluate the efficacy and safety of aztreonam in treating pulmonary infections caused by Pseudomonas aeruginosa in CF patients.
- To compare aztreonam's effectiveness against traditional combination therapies.
Main Methods:
- Review of controlled clinical trials investigating aztreonam therapy in CF patients.
- Analysis of treatment outcomes and adverse events associated with aztreonam use.
Main Results:
- Aztreonam demonstrated clinical efficacy in treating pulmonary exacerbations caused by P. aeruginosa in CF patients.
- The primary side effect observed was transient elevation of hepatic transaminases, of uncertain clinical significance.
- Efficacy appeared comparable to tobramycin plus azlocillin combination therapy.
- No significant difference in resistance development was noted compared to traditional treatments.
Conclusions:
- Aztreonam is an effective therapeutic option for Pseudomonas aeruginosa pulmonary infections in cystic fibrosis.
- It offers comparable efficacy to existing combination therapies with a manageable side effect profile.
- Aztreonam represents a valuable alternative, potentially with lower resistance development risk.